Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7388057 | PMC |
| http://dx.doi.org/10.1038/s41590-019-0428-8 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
[Pathological consequences of excess of interferon in vivo].
Med Sci (Paris)
March 2019
CNRS, Paris, France.
In this brief review, the authors present a history of the different aspects of the scientific puzzle leading from pioneer animal studies and astute clinical experimental observations to a mature appreciation of the deleterious role of excess of a type I interferon in human pathology.
View Article and Find Full Text PDFA Brief Historical Perspective on the Pathological Consequences of Excessive Type I Interferon Exposure In vivo.
J Clin Immunol
August 2018
C.N.R.S, Paris, France.
Interferon should be used to prevent and/or treat Ebola virus disease.
Biomed Pharmacother
April 2015
CNRS, Paris, France. Electronic address:
On intuition and the discovery of interferon.
Cytokine Growth Factor Rev
April 2015
Centre National de Recherche, France. Electronic address:
Selective expression of inhibitory Fcgamma receptor by metastatic melanoma impairs tumor susceptibility to IgG-dependent cellular response.
Int J Cancer
December 2008
INSERM, U872, Microenvironnement immunitaire et tumeurs, Equipe 13, Centre de Recherche des Cordeliers, Paris, France.
During melanoma progression, patients develop anti-tumor immunity including the production of anti-tumor antibodies. Although the strategies developed by malignant cells to escape anti-tumor cellular immunity have been extensively investigated, little is known about tumor resistance to humoral immunity. The main effect of IgG antibodies is to activate the immune response by binding to host Fc gamma receptors (FcgammaR) expressed by immune cells.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!